Skip to main content

11.04.2018 | Original Article | Ausgabe 5/2018

Comparative Clinical Pathology 5/2018

Hematological, biochemical, serological, and molecular monitoring of blood donor dogs vaccinated with CaniLeish® for the prevention of Leishmaniosis

Comparative Clinical Pathology > Ausgabe 5/2018
Viola Vannucci, Alessandra Gavazza, Anyela Andrea Medina Valentin, Veronica Gori, George Lubas


The use of systemic preventive measures in dogs living in areas with Leishmania infection is advisable, particularly in blood donors. The aim of this study was to monitor healthy blood-donor dogs immunized with the vaccine CaniLeish® by means of hematological, biochemical (serum total protein, albumin, protein electrophoresis, and C-reactive protein), serological (Speed Leish K™ and IFAT), and molecular assays (qualitative PCR, qlPCR). Twenty-four dogs were monitored at (T0), second (T1), third (T2) immunizations, and 2 months (T3) after the initial immunization and at the first (T4), second (T5), and third (T6) annual booster. The results were as follows: slight hyperproteinemia (29.5%, p > 0.05) observed throughout the monitoring period (T0-T6); increase in C-reactive protein (46.4%, p < 0.05) (at T3-T6); significant alterations in β-1 and β-2 globulin fractions (as absolute and percentage values, p < 0.05), Speed Leish K™ assay negative at T0 and T4-T6, positive IFAT titres of 1/40 (9.5%) at T0, and T3-T6, 1/80 (8.6%) at T1-T4, 1/160 (6.7%) at T1-T2 and T4, and 1/320 (1.9%) at T2 and T4; and qlPCR positive in 7.7% of samples at T3-T6. The vaccination with Canileish® induced changes in a few clinico-pathological and serological markers, which are likely associated with the activation of the immune response. These changes should be carefully considered when evaluating vaccinated dogs included in blood transfusion programs. The use of the CaniLeish® vaccine could be recommended as an additional preventive measure and could represent an important practice in the field of canine transfusion medicine.

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

e.Med Interdisziplinär

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

Über diesen Artikel

Weitere Artikel der Ausgabe 5/2018

Comparative Clinical Pathology 5/2018 Zur Ausgabe

Neu im Fachgebiet Pathologie

07.03.2019 | Mammakarzinom | CME | Ausgabe 2/2019

Update der S3-Leitlinie Mammakarzinom

Was gibt es Neues für Pathologen?

21.02.2019 | Schwerpunkt: Neuropathologie | Ausgabe 2/2019

Neuropathologie der Medulloblastome und anderer embryonaler Tumoren des ZNS

Präzisierung der Diagnostik durch Integration genetischer Marker

21.02.2019 | Schwerpunkt: Neuropathologie | Ausgabe 2/2019

Integrierte Diagnostik der diffusen astrozytären und oligodendroglialen Gliome

04.02.2019 | Schwerpunkt: Gynäkopathologie | Ausgabe 1/2019 Open Access

Fallstricke und Probleme bei der Differenzialdiagnose epithelialer Ovarialtumoren